EXPANDING ACCESS TO HEALTH
We are committed to bringing more medicines to more people and helping to improve health around the world. Our efforts are focused on building sustainable solutions to expand access to medicines and health care for underserved patients worldwide. We continue to explore models and approaches that are tailored to the needs of patients in different geographies with different needs.
It is often suggested that the price of medicine and enforcement of intellectual property rights are the main barriers to access to medicines in poor populations. Access to medicines is a complex issue, with the greatest impact coming from lack of health care infrastructure. We believe that protection of intellectual property and sustainable pricing are essential to our ability to discover and develop new medicines, and bring them to patients in need. Given the complexity of access issues and the need for a holistic approach to solving them, we work closely with governments and other stakeholders to address health care challenges and improve health around the world. We are also taking innovative approaches to pricing, including tiered pricing both across and within countries.
Building Health Care Infrastructure
and Capacity Worldwide
Pfizer helps build health care infrastructure and capacity primarily in two ways:
- By working in partnership with non-government organizations, government agencies, multilateral aid organizations and other global health stakeholders to strengthen health care systems and improve care.
- Through product donation and patient assistance programs that improve access to our medicines.
A synopsis of our social investment programs may be found here.
These investments include programs that provide direct assistance, such as product donations and steep discounts, to help bridge current gaps in health care delivery to various underserved populations. For example, we donate Zithromax to fight blinding trachoma and Diflucan to fight opportunistic fungal infections associated with HIV and AIDS in the developing world. Pfizer Helpful Answers helps eligible patients in the U.S. with their Pfizer prescriptions for free or at a savings and, in some cases, offers reimbursement support services.
Partnering to Advance R&D for Diseases
of the Underserved
Pfizer is committed to and collaborating on developing effective treatments for diseases that disproportionately affect the underserved, including HIV/AIDS, tuberculosis and otherwise neglected tropical diseases.
WIPO Re:Search is an R&D consortium dedicated to developing new solutions—including medicines, vaccines and diagnostics—for neglected tropical diseases, malaria and tuberculosis. The consortium was created in partnership with the World Intellectual Property Organization (WIPO), BIO Ventures for Global Health and other leaders in the R&D pharmaceutical industry.
ViiV Healthcare is a global specialist HIV company established by Pfizer and GlaxoSmithKline in 2009 to deliver advances in treatment and care for people living with HIV. Shionogi joined ViiV Healthcare in 2012. ViiV Healthcare aims to take a deeper and broader interest in HIV/AIDS than any company has done before, while taking a new approach to deliver effective and new HIV medicines, as well as to support communities affected by HIV.
Developing Viable Business Models
to Serve the Underserved
We are developing a portfolio of innovative business approaches and models as part of our strategy to increase access to our medicines and improve health care for underserved populations in both developed and developing countries. We are also taking innovative approaches to pricing in various markets, including tiered pricing both across and within countries, and portfolio offerings that address and balance customers' cost sensitivities.
Providing Important Medicines Through Institutional Buyers
We work closely with global institutional buyers who purchase medicines for the neediest of patients. For example, Pfizer has long-standing business partnerships with both the U.S. Agency for International Development and the United Nations Population Fund to make our injectable contraceptive, Depo-Provera, available to women all across the globe, from sub-Saharan Africa to Southeast Asia to Latin America. We are working to expand our relationship with such institutional buyers to make a broad portfolio of our medicines accessible to as many low income patients as possible.
National Immunization Programs
We seek to make accessible our potentially life-saving vaccines through national immunization programs (NIPs), an important channel that provides an organized system of vaccine procurement and utilization for countries and agencies around the world. The overarching goal of such programs is to ensure proper delivery and utilization of vaccines in a cost-effective and efficient manner. Over many years, Pfizer has successfully collaborated with more than 60 governments in developed, developing and emerging markets worldwide to establish or maintain pneumococcal disease prevention programs that help to protect nearly 30 million children.
Bringing Prevenar 13 to
Children in Need
We are committed to helping protect millions of infants and young children in the developing world from pneumococcal disease, the leading cause of vaccine-preventable death in young children. Under the auspices of the GAVI Alliance's Advance Market Commitment (AMC) for pneumococcal vaccines, Pfizer will supply up to 480 million doses of Prevenar 13 through 2023. Within only two years of the launch of the AMC, Prevenar 13 is available in 20 GAVI-eligible countries, with many additional launches planned.
Our social investments focus on effective and sustainable health care delivery for underserved patients while empowering our colleagues, strengthening our stakeholder relationships, and ultimately having a positive impact on society and our business.
For an interactive map of all our access-related programs, see here.
|Pfizer Helpful Answers||Provide Pfizer medicines for free or at a savings to patients who qualify.||U.S.||Enabled more than 3.4 million uninsured or underinsured patients to get access to nearly 39.2 million Pfizer prescriptions from 2008 to 2012.|
|Infectious Disease Institute||Build capacity for prevention, treatment, training, research and clinical services in Uganda.||Africa||Provide ongoing care and treatment to more than 36,500 patients, with outreach to 688,000 individuals; more than 10,300 health care workers from 28 countries received training in HIV/AIDS since program inception.|
|Global Health Fellows||Improve access, quality and efficiency of health services for underserved populations through individual three to six month assignments and two to three week team volunteer assignments.||Global—Africa, Asia, Latin America, Europe, U.S.||Since 2003, 377 colleagues have completed an estimated 334,000 hours of skills-based volunteering, which is valued at approximately $49 million of pro bono service to partner organizations throughout the world. Through GHF, Pfizer has partnered with more than 40 international development organizations in more than 40 countries. 2013 marks the 10th anniversary of the program.|
|International Trachoma Initiative||Goal to eliminate trachoma by 2020 through the donation of Zithromax and an integrated public health strategy.||Africa, Asia, Latin America||Pfizer has shipped more than 340 million Zithromax treatments to date.|
|Mobilize Against Malaria||Educate treatment providers and patients to improve malaria treatment.||Ghana, Kenya, Senegal||Over 1,200 Licensed Chemical Sellers trained to correctly dose and administer ACTs, and to recognize and refer complicated malaria cases in Ghana. Over 1,600 staff trained to advise women on prevention and treatment of malaria in Kenya. Over 200 community health workers and nurses trained in malaria diagnosis and treatment at 24 health huts in Senegal.|
|Global Health Partnership||Strengthen innovative public health partnerships that address challenges in cancer and tobacco control, in support of the noncommunicable diseases movement.||47 countries in Asia, Latin America, Europe, Africa, North America||More than 97,000 patients served and 266,000 health care workers trained from 2008 to 2011.|
|Diflucan Partnership Program||Donate Diflucan for the treatment of two opportunistic infections associated with HIV and AIDS: cryptococcal meningitis and esophageal candidiasis.||63 countries in Africa, Asia, Latin America||Over a 12-year period, the program has provided over $1.3 billion in medicine to more than 2,600 sites in 63 countries.|